

Fibroblast Growth Factor-23 (FGF23), In Situ Hybridization

#### Overview

#### **Useful For**

Assessing fibroblast growth factor-23 (FGF23) expression

#### **Method Name**

In Situ Hybridization (ISH)

#### **NY State Available**

Yes

# Specimen

## **Specimen Type**

Special

## Additional Testing Requirements

If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.

## **Shipping Instructions**

Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.

### **Necessary Information**

A pathology/diagnostic report and a brief history are required.

## Specimen Required

**Specimen Type:** Tissue

Supplies: Pathology Packaging Kit (T554)

Submit:

Formalin-fixed, paraffin-embedded tissue block

OR

5 Unstained, positively charged glass slides; sections 4-microns thick

## **Forms**

If not ordering electronically, complete, print, and send a <u>Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains</u>
Request (T763) with the specimen.

## **Reject Due To**

Wet/frozen	Reject



Fibroblast Growth Factor-23 (FGF23), In Situ Hybridization

tissue	
Cytology	Reject
smears	
Nonformalin	Reject
fixed tissue	
Nonparaffin	Reject
embedded	
tissue	
Noncharged	Reject
slides	
ProbeOn slides	Reject
Snowcoat	Reject
slides	

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Special	Ambient (preferred)		
	Refrigerated		

# Clinical & Interpretive

# **Clinical Information**

Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone that acts on the proximal renal tubules to block phosphate reuptake. Production of FGF23 by a particular mesenchymal tumor, phosphaturic mesenchymal tumor, is responsible for the great majority of cases of tumor-induced osteomalacia.

#### Interpretation

This test, when not accompanied by a pathology consultation request, will be reported as either positive or negative. If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.

# **Cautions**

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.

The charge of glass slides can be affected by environmental factors and subsequently may alter slide staining. Sending unsuitable glass slides can result in inconsistent staining due to poor slide surface chemistry.

Best practices for storage of positively charged slides:

- -Minimize time slides are stored after being unpackaged
- -Limit exposure to high humidity and heat

#### **Clinical Reference**



Fibroblast Growth Factor-23 (FGF23), In Situ Hybridization

- 1. Carter JM, Caron BL, Dogan A, Folpe AL. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. AM J Surg Pathol. 2015;39:(1)75-83
- 2. Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: State of the field and future directions. Trends Endocrinol Metab. 2012;23(12):610-618
- 3. Graham RP, Hodge JC, Folpe AL, et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum Pathol. 2012;43(8):1334-1338
- 4. Graham R, Krishnamurthy S, Oliveira A, Inwards C, Folpe AL. Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas. J Clin Pathol. 2012;65(10):907-909
- 5. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009;33(9):1348-1354
- 6. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity-an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30

#### **Performance**

## **Method Description**

In situ hybridization on sections of paraffin-embedded tissue. (Unpublished Mayo method)

## **PDF Report**

No

### Day(s) Performed

Monday through Friday

# **Report Available**

5 to 8 days

#### **Specimen Retention Time**

Until staining is complete

# **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

# Fees & Codes

### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.



Fibroblast Growth Factor-23 (FGF23), In Situ Hybridization

## **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

## **CPT Code Information**

88365-Primary

# **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
23FBG	Fibroblast Growth Factor-23, ISH	104259-7

Result ID	Test Result Name	Result LOINC® Value
620250	Interpretation	50595-8
620251	Participated in the Interpretation	No LOINC Needed
620252	Report electronically signed by	19139-5
620253	Material Received	81178-6
620254	Disclaimer	62364-5
620255	Case Number	80398-1